NCT06501976View on ClinicalTrials.gov

An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG

Lurbinectedin

2.6 mg/m2 , Given IV, every 21 days

RADIATION

Radiation Therapy

Thoracic radiotherapy

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06501976 - An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy | Biotech Hunter | Biotech Hunter